← All Kyverna Therapeutics, INC filings

Kyverna Therapeutics, INC 10-K annual reports

Annual reports — audited financials, the full risk-factor list, and management’s account of the year.

NASDAQ
KYTX
Kyverna Therapeutics, INC
10-K: Kyverna Therapeutics Reports 2024 Financial Results, Highlights Clinical Progress in Autoimmune Disease Therapies
Kyverna Therapeutics' 10-K filing summarizes the company's focus on developing cell therapies for autoimmune diseases, highlighting clinical trial progress and financial results for 2024.
NASDAQ
KYTX
Kyverna Therapeutics, INC
10-K: Kyverna Therapeutics Outlines Capital Structure and Corporate Governance in 10-K Filing
Kyverna Therapeutics' 10-K filing details its capital stock, governance structure, and key agreements, highlighting its focus on cell therapies for autoimmune diseases.